A Randomized, Placebo-controlled, Partially Blinded Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of BCG Revaccination, H4:IC31, and H56:IC31 in Healthy, HIV-1-Uninfected Adolescent Participants
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2017
At a glance
- Drugs H4IC (Primary) ; H56IC (Primary) ; BCG vaccine
- Indications Tuberculosis
- Focus Adverse reactions; Pharmacodynamics
- Acronyms A-042
- Sponsors Aeras
- 10 Jun 2017 Biomarkers information updated
- 23 Jan 2017 Status changed from active, no longer recruiting to completed.
- 11 Jul 2016 Planned End Date changed from 1 May 2016 to 1 Dec 2016.